NEW YORK, Jan. 31 /PRNewswire-FirstCall/ -- Inyx, Inc. , a specialty pharmaceutical company focused on niche drug-delivery technologies and products, announced today that its wholly owned United Kingdom subsidiary Ashton Pharmaceuticals has been selected by Acorus Therapeutics, Ltd., a privately owned U.K.-based pharmaceutical company specializing in unique, essential medicines and medical devices, to manufacture and package a prescription-only, solid-dose product for the treatment of various forms of epilepsy and essential tremor.
Ashton is in the process of concluding process validation, method transfer and stability studies to permit commercial production of this drug to commence. Acorus and Ashton have now signed an initial three-year agreement whereby the Inyx subsidiary will be the producer of the product in a variety of dosages and packaging formats for distribution in more than 10 Western European and South American markets.
Jack Kachkar, M.D., Chairman and CEO of Inyx, Inc., said, "This contract reflects Ashton's strong solid-dose expertise, Inyx's growing packaging capabilities, and our expanding presence in global markets. We are very pleased that Ashton has been selected by Acorus Therapeutics, which is a new client for our company."
Acorus Therapeutics is a privately owned U.K.-based pharmaceutical company specializing in unique, essential medicines and medical devices that fulfill unmet medical needs. Acorus focuses on project management, regulatory affairs, marketing and business development, while outsourcing operations such as research, development, manufacturing and logistics. The company's corporate offices are in Hamsterley, County Durham, U.K. For more information, please visit: www.acorus-therapeutics.com.
Inyx, Inc. is a specialty pharmaceutical company with niche drug-delivery technologies and products for the treatment of respiratory, allergy, dermatological, topical and cardiovascular conditions. Inyx focuses its expertise on both prescription and over-the-counter pharmaceutical products, and provides specialty pharmaceutical development and production consulting services. In addition, Inyx is developing its own proprietary products. The company's operations are conducted through several wholly owned subsidiaries: Inyx USA Ltd., based in Manati, Puerto Rico; Inyx Pharma Ltd. and Inyx Europe Limited, which owns and operates Ashton Pharmaceuticals Ltd., all near Manchester, England; Inyx Canada, Inc. in Toronto; and Exaeris, Inc., based in Exton, Pennsylvania, which conducts Inyx's marketing and distribution activities. Inyx, Inc.'s corporate offices are in New York City. For more information, please visit: www.inyxgroup.com.
Statements about the Inyx's future expectations, including future revenues and earnings, and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. Inyx intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, Inyx's actual results could differ materially from expected results.
For more information, please contact:
Jay M. Green, Executive Vice President of Inyx, Inc.
Bill Kelly, Vice President, Investor Relations of Inyx, Inc.